EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

CARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases

Bhadran Bose iD, Simon A Carter, Mia E Abdy iD, Nicole Scholes-Robertson iD, Ieyesha Roberts, Tze Liang Goh, Vincent Lee iD, Emily See iD, Helen Coolican, Vanessa Cullen, Min Jun iD, Rathika Krishnasamy iD und 7 weitere

Nephrology · 2025

DOI: 10.1111/nep.70119 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Nephrology, 2025. Verfasst von Bhadran Bose und 18 weiteren Autor:innen. Beteiligte Einrichtung: Australasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Glomerulonephritis, Kidney Glomerulus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The KDIGO 2021 Glomerular Disease Guidelines provide updated recommendations on the management of glomerular diseases (GD), with substantial advances made in diagnosis, treatment, and improvement of outcomes for people with GD.

Methods

The Caring for Australians and New Zealanders with kidney Impairment (CARI) Guidelines commentary contextualises the updated guidelines for the Australian and New Zealand setting.

Results

Kidney biopsy remains central to diagnosis, with validated scoring systems available. However, genetic testing for suspected monogenic kidney disease is now accessible in Australia, enabling earlier diagnosis and management, particularly in situations where a kidney biopsy is considered high risk or contraindicated. The guideline emphasises timed urine collections for protein excretion over spot tests and we suggest the use of the CKiD u25 eGFR equation for people under 25. For IgA nephropathy (IgAN) and IgA vasculitis (IgAV), emerging therapies such as targeted‐release budesonide and sparsentan demonstrate promise but await approval and public subsidy in our region. For membranous nephropathy, the guideline highlights the differences in adult and paediatric management. In nephrotic syndrome, tacrolimus is used as first‐line therapy and rituximab as a second‐line agent for steroid‐dependent or frequently relapsing disease. Minimal change disease recommendations include glucocorticoid tapering after remission, while focal segmental glomerulosclerosis incorporates genetic classifications and advocates for next‐generation sequencing.

Conclusion

Our commentary underscores the need for increased participation in clinical trials to validate regional applicability and improve long‐term outcomes for people with GD in Australia and New Zealand. Clinical trials of new medications have led to more treatment options that are awaiting approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlomerulonephritisKidney GlomerulusHumansAustraliaBiopsyGlomerulonephritis, IGANew Zealand

Stichwörter der Autor:innen

IgA nephropathyantineutrophil cytoplasmic antibody (ANCA)glomerulonephritis (GN)guidelineslupus nephritisnephrotic syndrome

Autor:innen und Institutionen

  • Australasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia.
  • Department of Nephrology, Nepean Hospital, Kingswood, Australia.
  • Department of Nephrology, The Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia.
  • Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
  • Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.

ORCID-Profile: Bhadran Bose, Mia E Abdy, Nicole Scholes-Robertson, Vincent Lee, Emily See, Min Jun, Rathika Krishnasamy, Kelly Lambert, Jonathan Craig, Casey Light, Carla Scuderi, David J Tunnicliffe

Zitieren

APA

Bose, B., Carter, S. A., Abdy, M. E., Scholes-Robertson, N., Roberts, I., Goh, T. L., Lee, V., See, E., Coolican, H., Cullen, V., Jun, M., Krishnasamy, R., Lambert, K., Craig, J., Light, C., Nguyen, T., Scuderi, C., Tunnicliffe, D. J., & Viecelli, A. K. (2025). CARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. Nephrology. https://doi.org/10.1111/nep.70119

Vancouver

Bose B, Carter SA, Abdy ME, Scholes-Robertson N, Roberts I, Goh TL, et al. CARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. Nephrology. 2025. doi:10.1111/nep.70119

BibTeX
@article{Bose2025,
  author = {Bose, Bhadran and Carter, Simon A and Abdy, Mia E and Scholes-Robertson, Nicole and Roberts, Ieyesha and Goh, Tze Liang and Lee, Vincent and See, Emily and Coolican, Helen and Cullen, Vanessa and Jun, Min and Krishnasamy, Rathika and Lambert, Kelly and Craig, Jonathan and Light, Casey and Nguyen, Thu and Scuderi, Carla and Tunnicliffe, David J and Viecelli, Andrea K},
  title = {CARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases},
  journal = {Nephrology},
  year = {2025},
  doi = {10.1111/nep.70119}
}
Kostenlos starten →